25 results
Thumbnail

D2.332 - First reported case of IgE-mediated food allergy to Tetragonia tetragonioides (New Zealand spinach)

Thumbnail

D2.337 - REMA Score Outperforms C-kit and Tryptase in Identifying Mast Cell Disorders in Hymenoptera Venom Allergy

Thumbnail

D2.347 - Filaggrin Mutation in a Patient with Ant Anaphylaxis: Case Report and Literature Review

Thumbnail

D2.333 - Glatiramer acetate: when immunomodulation is not enough

Thumbnail

D2.335 - Single-nucleotide polymorphisms in the Mas-related G protein-coupled receptor X2 alter in vitro cellular responses to specific drugs

Thumbnail

D2.336 - Risk of systemic reactions among school-age children sensitized to fish, crustaceans and molluscs

Thumbnail

D2.338 - Gaps in Adrenaline Autoinjector Education Among Patients at Risk of Anaphylaxis: A Cross-Sectional Study

Thumbnail

D2.340 - Improving Post-Anaphylaxis Referral Pathways in the Emergency Department: A Quality Improvement Initiative

Thumbnail

D2.341 - Comparative Evaluation of Diagnostic Criteria for Food Allergy–Induced Anaphylaxis: Accuracy, Clinical Applicability, and Validation

Thumbnail

D2.342 - Environmental Exposure Predicts Severity of Hymenoptera Venom Anaphylaxis Better Than Classical Biomarkers: Added Value of Component-Resolved Diagnostics

Thumbnail

D2.343 - Anaphylactic Reaction to Methylprednisolone Acetate in a Young Adult

Thumbnail

D2.344 - National Data on Anaphylaxis in Brazil: Findings from the Brazilian Registry

Thumbnail

D2.345 - Successful Desensitization in a Pediatric Patient Who Developed an Immediate-Type Systemic Hypersensitivity Reaction to FVIII/vWF Concentrate

Thumbnail

D2.346 - When cold triggers anaphylaxis

Thumbnail

D2.490 - Consistent efficacy of a seasonal 300IR birch pollen sublingual immunotherapy in children and adolescents during worst pollen exposure: results of the YOBI trial

Thumbnail

D2.491 - Efficacy of a 300IR birch liquid sublingual immunotherapy during the alder and hazel pollen seasons: results of the YOBI trial

Thumbnail

D2.492 - Efficacy and safety of a 300IR daily dose of a SLIT of birch pollen allergen extract in children and adolescents with allergic rhinoconjunctivitis: results from the YOBI trial

Thumbnail

D2.494 - Tralokinumab treatment in adults with atopic dermatitis who were previously treated with dupilumab: 12-months real-world data from the TRACE study

Thumbnail

D2.495 - Treatment with Izicopan (INF904), an oral anti-C5aR inhibitor improves efficacy and safety in patients with chronic spontaneous urticaria: results from a Phase 2a study

Thumbnail

D2.496 - First-in-Human Phase I Clinical Outcomes of BxC-I17e Enriched with HSP70/miR-22-3p in Atopic Dermatitis